Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Work In Process (2018 - 2025)

Immucell (ICCC) has disclosed Work In Process for 8 consecutive years, with $6.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Work In Process fell 2.81% year-over-year to $6.0 million, compared with a TTM value of $6.0 million through Sep 2025, down 2.81%, and an annual FY2024 reading of $5.7 million, down 1.18% over the prior year.
  • Work In Process was $6.0 million for Q3 2025 at Immucell, up from $5.6 million in the prior quarter.
  • Across five years, Work In Process topped out at $6.1 million in Q3 2024 and bottomed at $1.4 million in Q1 2021.
  • Average Work In Process over 5 years is $5.1 million, with a median of $5.6 million recorded in 2024.
  • The sharpest move saw Work In Process soared 69.55% in 2021, then dropped 2.81% in 2025.
  • Year by year, Work In Process stood at $1.4 million in 2021, then skyrocketed by 142.14% to $3.5 million in 2022, then surged by 67.65% to $5.8 million in 2023, then fell by 1.18% to $5.7 million in 2024, then grew by 3.58% to $6.0 million in 2025.
  • Business Quant data shows Work In Process for ICCC at $6.0 million in Q3 2025, $5.6 million in Q2 2025, and $5.8 million in Q1 2025.